Immediate Impact
7 standout
Citing Papers
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
2023 Standout
COVID-19 and its long-term sequelae: what do we know in 2023?
2023 Standout
Works of R. Sabarinathan being referenced
Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021-January 2022
2022
Epidemiology of chikungunya based on laboratory surveillance data—India, 2016–2018
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| R. Sabarinathan | 175 | 99 | 37 | 47 | 20 | 236 | |
| Maria Grazia Colao | 140 | 23 | 32 | 20 | 22 | 230 | |
| Jyotsnamayee Sabat | 130 | 86 | 9 | 14 | 21 | 173 | |
| Chamara Dalugama | 138 | 172 | 15 | 14 | 29 | 281 | |
| Dongmei Wang | 200 | 37 | 15 | 34 | 22 | 286 | |
| Fatemeh Zali | 178 | 39 | 60 | 7 | 17 | 284 | |
| Amjad Khan | 167 | 15 | 67 | 27 | 17 | 285 | |
| Matthias L. Schmid | 109 | 77 | 14 | 18 | 15 | 263 | |
| Maritza González | 105 | 186 | 11 | 6 | 18 | 241 | |
| Bibek Kumar Lal | 94 | 98 | 8 | 26 | 16 | 258 | |
| Anne Frosch | 65 | 195 | 5 | 32 | 18 | 286 |
All Works
Loading papers...